BLOX Markets, Inc. and OptimX Markets Enter into Early-Stage Partnership
19 déc. 2024 09h06 HE
|
BLOX Markets, Inc.; OptimX Markets
Joint Press Release NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- BLOX Markets, Inc. is excited to announce an early-stage partnership with OptimX Markets, an innovative liquidity management...
Employ Inc. Announces Promotion of Stephanie Manzelli to Chief Human Resources Officer
06 nov. 2024 07h00 HE
|
Employ Inc.
Employ Promotes Stephanie Manzelli to CHRO
Employ Inc. Appoints Joey Humke as Chief Revenue Officer
23 sept. 2024 07h00 HE
|
Employ Inc.
Employ Inc. Appoints Joey Humke as Chief Revenue Officer
Kula debuts the first complete hiring platform with purpose-built AI for recruiting
19 sept. 2024 10h00 HE
|
Kula
San Francisco, California, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The rise of AI has transformed the recruiting playbook. At least 62 percent of recruiters expressed optimism about AI’s impact on...
Employ Inc. Opens Center of Excellence in Denver
18 sept. 2024 07h00 HE
|
Employ Inc.
Employ Inc. Opens Center of Excellence in Denver
Pico Partners with Blue Ocean Technologies for After-Hours US Equities Trading Expanding PicoNet’s Capabilities
09 juil. 2024 07h00 HE
|
Pico
Pico clients gain direct access to Blue Ocean Technologies ATS, unlocking expanded capabilities for US equities trading for after-hours trading.
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
22 mai 2024 11h20 HE
|
Kymera Therapeutics, Inc.
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting ...
Upstream Bio Presents Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society International Conference
22 mai 2024 11h15 HE
|
Upstream Bio, Inc.
Positive results from a Phase 1 dose ranging study of verekitug (UPB-101) in asthma presented at ATS 2024
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
21 mai 2024 14h30 HE
|
InflaRx N.V.
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data...
Upstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference
15 mai 2024 07h00 HE
|
Upstream Bio, Inc.
Upstream Bio will present clinical data from dose-ranging study of verekitug (UPB-101) in adults with asthma at the American Thoracic Society conference